Navigation Links
VASAMED(R) Appoints Craig M. Walker, MD to Board of Directors
Date:7/29/2008

MINNEAPOLIS, July 29 /PRNewswire-FirstCall/ -- VASAMED, INC. (Pink Sheets: VSMD) announced today that Craig M. Walker, M.D., has been elected to the Company's board of directors increasing the number of directors from four to five. Dr. Walker brings over 25 years of medical experience as a practicing cardiologist, clinical investigator and thought leader.

"Dr. Walker will be a great addition to our board. As one of the world's leading experts in the care of patients with peripheral vascular disease as well as the advances in the technology in support of this mission, Dr. Walker will bring tremendous insight and perspective to our organization," said Paulita LaPlante, VASAMED, president and chief executive officer.

Dr. Walker is the Founder, President, and Medical Director of the Cardiovascular Institute of the South; Medical Director of the CIS Cardiovascular Fellowship Training Program; Associate Clinical Professor of Medicine Tulane University School of Medicine; and Medical Director of the Cardiac Catheterization Laboratory at Terrebonne General Medical Center.

Dr. Walker has been Principal Investigator in many cardiovascular medical device clinical trials, and has made numerous presentations before the FDA, medical conferences and symposia. He has published over 100 articles, abstracts and books. He is a graduate of the Louisiana State University School of Medicine and is certified by the American Board of Internal Medicine, American College of Physicians, American Board of Internal Medicine -- Subspecialty of Cardiovascular Disease, American College of Cardiology, American College of Angiology, American Society for Laser Medicine and Surgery and Diplomat in Interventional Cardiology. Dr. Walker completed his cardiology training at Harvard University's Brigham and Women's Hospital, where he was a research fellow and clinical instructor in cardiology and medicine.

Dr. Walker is intimately involved in advancing innovative technology to improve patients' lives. He is a Board of Director member for Cardiva, CV Therapeutics, IDev and Spectranetics. He is a consultant to Boston Scientific, Cardiva, CV Therapeutics, ev3, FlowMedica, IDev, Possis and Spectranetics, serves on the speaker's bureau for Abbott, AstraZeneca, Boston Scientific, Cardiva, Cordis, CV Therapeutics, FlowMedica, Possis, Spectranetics and Toshiba; and is on the medical/scientific advisory board for Cardiva, Edwards Lifesciences, FlowMedica, Philips, Spectranetics and The Medicine Company.

Commenting on his board appointment, Dr. Walker said, "VASAMED, is committed to bringing the best noninvasive diagnostic hemodynamic products to the medical community. In practice I have found the SensiLase(R) System's skin perfusion pressure technology to be a valuable tool to effectively identify patients with peripheral vascular disease, confirm clinical outcomes and assist with patient care decisions."

About VASAMED, INC.

VASAMED designs, licenses, manufactures and distributes products that are used by physicians in their clinic or procedure lab to determine a patient's hemodynamic and lower extremity arterial health. VASAMED products and technology are focused on measuring critical cardiovascular and peripheral information and include SensiLase(R) Skin Perfusion Pressure and Pulse Volume Recording System to measure capillary perfusion, AcQtrac(TM) System to monitor heart function, and Tissue Carbon Dioxide Technologies, featuring the MicroStat(TM) System, to monitor tissue wellness.


'/>"/>
SOURCE VASAMED, INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... ... 2017 , ... “Finding Christ Through Social Media: Year One ... the writer’s path toward true communion with God. “Finding Christ Through Social Media: ... creation of published author Lea Michelle Johnson, a follower of Christ, wife and ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, ... advanced medical technology for non-invasive surgery, announced today ... System for treatment of uterine fibroids throughout the ... had received approval from the US Food and ... the Mirabilis System in the United States.  The ...
Breaking Medicine Technology: